| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1092669253 |
| P356 | DOI | 10.1038/S41598-017-16074-1 |
| P932 | PMC publication ID | 5694000 |
| P698 | PubMed publication ID | 29150684 |
| P50 | author | Hua Qu | Q51301958 |
| Hongting Zheng | Q56479724 | ||
| P2093 | author name string | Yi Zheng | |
| Rui Zhang | |||
| Zhenqi Liu | |||
| Gangyi Yang | |||
| Yuren Wang | |||
| Xiongzhong Ruan | |||
| P2860 | cites work | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies | Q26765047 | ||
| Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis | Q27002540 | ||
| The Cochrane Collaboration's tool for assessing risk of bias in randomised trials | Q27860509 | ||
| Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860868 | ||
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 | Q29616834 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Medical significance of peroxisome proliferator-activated receptors. | Q33333867 | ||
| A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population | Q33750513 | ||
| Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis | Q34065266 | ||
| Quantitative methods in the review of epidemiologic literature | Q34187297 | ||
| Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies | Q34324440 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. | Q34671802 | ||
| Pioglitazone use and risk of bladder cancer: population based cohort study | Q34676639 | ||
| Cohort study of pioglitazone and cancer incidence in patients with diabetes | Q34718437 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study | Q34990890 | ||
| Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer. | Q50686596 | ||
| Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus | Q59656664 | ||
| Median follow-up in clinical trials | Q68177585 | ||
| Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes | Q85642529 | ||
| Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety | Q87105512 | ||
| Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study | Q87398836 | ||
| Pioglitazone and thyroid cancer risk in Taiwanese patients with type 2 diabetes 2 | Q87473386 | ||
| Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes | Q88008106 | ||
| Pioglitazone and bladder cancer: a population-based study of Taiwanese. | Q35688201 | ||
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 | ||
| Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 | ||
| Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study | Q36050377 | ||
| The Clinical Significance of PPAR Gamma Agonism | Q36126682 | ||
| Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis | Q36247512 | ||
| The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. | Q36365241 | ||
| Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study | Q36486802 | ||
| Pioglitazone and bladder cancer: a propensity score matched cohort study | Q36562522 | ||
| Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. | Q36581133 | ||
| Pioglitazone after Ischemic Stroke or Transient Ischemic Attack | Q36953272 | ||
| Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights | Q37115436 | ||
| Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries | Q37179822 | ||
| Study design in medical research: part 2 of a series on the evaluation of scientific publications | Q37224830 | ||
| Breast cancer tumorigenicity is dependent on high expression levels of NAF-1 and the lability of its Fe-S clusters | Q37304967 | ||
| The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease | Q37464712 | ||
| Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. | Q37583052 | ||
| Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis | Q37736821 | ||
| Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. | Q38195439 | ||
| Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis | Q38417421 | ||
| Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study | Q38853757 | ||
| Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes | Q41107308 | ||
| Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration | Q42860408 | ||
| Pioglitazone use and the risk of bladder cancer. | Q43526947 | ||
| Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan | Q43748015 | ||
| Pioglitazone does not affect the risk of ovarian cancer: analysis of a nationwide reimbursement database in Taiwan | Q44072762 | ||
| Pioglitazone and oral cancer risk in patients with type 2 diabetes. | Q44220032 | ||
| Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study | Q44980532 | ||
| Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. | Q45974480 | ||
| Suspected drug-induced liver fatalities reported to the WHO database | Q46627287 | ||
| Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis | Q47613876 | ||
| Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. | Q47765250 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 15804 | |
| P577 | publication date | 2017-11-17 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes | |
| P478 | volume | 7 |
| Q64993013 | Association of Pioglitazone with Increased Risk of Prostate Cancer and Pancreatic Cancer: A Functional Network Study. | cites work | P2860 |
Search more.